New iron(III) anti-cancer aminobisphenolate/phenanthroline complexes: Enhancing their therapeutic potential using nanoliposomes

Matos, Carla; Albino, Melissa; Lopes, Joana; Viana, Ana S.; Côrte-Real, Leonor; Mendes, Filipa; Pessoa, João Costa; Tomaz, Ana Isabel; Reis, Catarina Pinto; Gaspar, Maria Manuela; Correia, Isabel

doi:10.1016/j.ijpharm.2022.121925

Cited by 6 publications

(1 citation statement)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The controlled delivery and targeting of loaded drugs at the cellular level overcoming the biological barriers is one of the added value of this type of option [43,44]. Currently, several types of nanosystems namely liposomes, solid lipid nanoparticles, and nanostructured lipid carriers and polymeric, metallic, and hybrid nanoparticles are under pre-clinical investigation [163][164][165][166][167][168][169][170][171][172][173][174][175][176][177][178][179]. Despite this, there is still no nanomedicine commercially available for patients with melanoma so far, being limited to volunteers in the different clinical trials.…”

Section: Completed and Undergoing Innovative Nanotechnological Approa...mentioning

confidence: 99%

Melanoma Management: From Epidemiology to Treatment and Latest Advances

Lopes

Rodrigues

Gaspar

et al. 2022

Cancers

Self Cite

View full text Add to dashboard Cite

Melanoma is the deadliest skin cancer, whose morbidity and mortality indicators show an increasing trend worldwide. In addition to its great heterogeneity, melanoma has a high metastatic potential, resulting in very limited response to therapies currently available, which were restricted to surgery, radiotherapy and chemotherapy for many years. Advances in knowledge about the pathophysiological mechanisms of the disease have allowed the development of new therapeutic classes, such as immune checkpoint and small molecule kinase inhibitors. However, despite the incontestable progress in the quality of life and survival rates of the patients, effectiveness is still far from desired. Some adverse side effects and resistance mechanisms are the main barriers. Thus, the search for better options has resulted in many clinical trials that are now investigating new drugs and/or combinations. The low water solubility of drugs, low stability and rapid metabolism limit the clinical potential and therapeutic use of some compounds. Thus, the research of nanotechnology-based strategies is being explored as the basis for the broad application of different types of nanosystems in the treatment of melanoma. Future development focus on challenges understanding the mechanisms that make these nanosystems more effective.

show abstract

Section: Completed and Undergoing Innovative Nanotechnological Approa...mentioning

confidence: 99%

Melanoma Management: From Epidemiology to Treatment and Latest Advances

Lopes

Rodrigues

Gaspar

et al. 2022

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

A step forward on the in vitro and in vivo assessment of a novel nanomedicine against melanoma

Pinho

Matias

Godinho‐Santos

et al. 2023

International Journal of Pharmaceutics

View full text Add to dashboard Cite

Nanocarrier-based Systems for Co-delivery of Drugs in the Management of Skin Cancer: A Review

Aqeel,

Hafeez,

Usmani

2023

CNANOM

View full text Add to dashboard Cite

Background: Cancer of the skin is one of the most frequent kinds of cancer around the globe and has substantial consequences for both public health and the economy. Co-delivery of drugs using nanotechnology are attractive for the reason that they make it possible for the effective targeting of medications with minimal side effects. The aim of the review is to provide an overview on the management of skin cancer with co-delivery via nanocarriers. Methods: Using a number of different search engines, search of the published literature was conducted using specific key terms such as co-delivery, skin cancer, nanoparticles, liposomes, and ethosomes. The articles were screened on the basis of target purpose and author’s expertise. Results: Nanocarriers based co-delivery systems have been found to improve the pharmacokinetic profile of medications, which resulted in enhanced therapeutic effectiveness with reduction in dose and side effects. Lipid based systems and polymeric nanoparticles have been utilized to incorporate different drugs with different physicochemical characteristics for the management of skin cancer. Conclusion: The management of skin cancer may be significantly manageable with co-drug delivery approach by integration of nanotechnology. Polymeric nanoparticles, liposomes, ethosomes, nanostructured lipid carriers and polymeric micelles have shown the potential for skin cancer treatment.

show abstract

New iron(III) anti-cancer aminobisphenolate/phenanthroline complexes: Enhancing their therapeutic potential using nanoliposomes

Cited by 6 publications

References 55 publications

Melanoma Management: From Epidemiology to Treatment and Latest Advances

Melanoma Management: From Epidemiology to Treatment and Latest Advances

A step forward on the in vitro and in vivo assessment of a novel nanomedicine against melanoma

Nanocarrier-based Systems for Co-delivery of Drugs in the Management of Skin Cancer: A Review

Contact Info

Product

Resources

About